Brain scans may reveal who will benefit from common antidepressant

NCT ID NCT05892744

Recruiting now Knowledge-focused Sponsor: University of Texas at Austin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find brain-based markers that can predict how individuals with major depression will respond to the antidepressant sertraline (Zoloft). Researchers will use fMRI and EEG brain scans to measure brain activity and connections before treatment. Fifty adults with chronic or recurrent depression will take sertraline for 8 weeks, and their symptom changes will be linked to their brain scan patterns. The goal is to personalize depression treatment by identifying which patients are most likely to benefit from this medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression major depressive disorder Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MAJOR DEPRESSION, RECURRENT MAJOR DEPRESSIVE DISORDER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600
RECRUITING

Austin, Texas, 78712, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••